After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms

INSUBCONTINENT EXCLUSIVE:

British-Swedish drug maker has gone from Beijing&s scrutiny to its praise, hailed as a sign of doing business in China.